Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
HEMORRHAGIC COMPLICATIONS OF INTRAVENOUS HEPARIN USE
Autore:
JUERGENS CP; SEMSARIAN C; KEECH AC; BELLER EM; HARRIS PJ;
Indirizzi:
ROYAL PRINCE ALFRED HOSP,DEPT CARDIOL,MISSENDEN RD SYDNEY NSW 2050 AUSTRALIA ROYAL PRINCE ALFRED HOSP,DEPT CARDIOL SYDNEY NSW 2050 AUSTRALIA
Titolo Testata:
The American journal of cardiology
fascicolo: 2, volume: 80, anno: 1997,
pagine: 150 - 154
SICI:
0002-9149(1997)80:2<150:HCOIHU>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRANSLUMINAL CORONARY ANGIOPLASTY; DEEP-VEIN THROMBOSIS; VASCULAR COMPLICATIONS; ANTICOAGULANT-THERAPY; SUBCUTANEOUS HEPARIN; VENOUS THROMBOSIS; INITIAL TREATMENT; UNSTABLE ANGINA; ASPIRIN; TRIAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
30
Recensione:
Indirizzi per estratti:
Citazione:
C.P. Juergens et al., "HEMORRHAGIC COMPLICATIONS OF INTRAVENOUS HEPARIN USE", The American journal of cardiology, 80(2), 1997, pp. 150-154

Abstract

To document the incidence of bleeding complications occurring in patients admitted to a cardiology service heated with intravenous heparin and to identify the major risk factors for these adverse events. intravenous heparin is effective treatment for a variety of cardiologic conditions but is associated with a number of adverse effects, including hemorrhage. During the study, 1,253 consecutive patients were admittedfor acute cardiac care and of these, 416 were treated with intravenous heparin. A total of 39 complications occurred in 37 heparin-treated patients (8.9%), of which 23 were hemorrhagic complications occurring in 21 heparin-treated patients (5.5%), Of these hemorrhagic complications, 12 were directly related to a vascular access site and 11 were apparently ''spontaneous'' hemorrhages, There was no apparent relation between the dose (mean 1,021 U/hour [range 531 to 1,882]) or duration (6.7 +/- 5.7 days) of heparin therapy and hemorrhagic complications. Ina multivariate analysis, female gender (odds ratio [OR] 4.76 [14.39 to 1.56]; p = 0.006), recent thrombolytic therapy (OR 12.9 [4.1 to 40.6]; p <0.0001), and a reduced admission hemoglobin (OR 1,41 [0.52 to 0.97]; p = 0.031) were significantly predictive of a hemorrhagic event. The incidence of cardiac catheterization procedures was not significantly higher in the complication group (OR 3.9 [0.84 to 18.4]; p = 0.082). Aspirin therapy, admission platelet count, and weight were noncontributory. Hemorrhagic complications occurred in 5.5% of patients receiving a continuous infusion of heparin. The use of thrombolytic therapy,female gender (independent of weight), and a reduced admission hemoglobin were significant independent predictors of hemorrhagic events, (C) 1997 by Excerpta Medico, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 14:06:16